U.S. Markets open in 2 hrs 14 mins

Spectrum Pharmaceuticals, Inc. (SPPI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4500-0.0277 (-5.80%)
At close: 04:00PM EDT
0.4579 +0.01 (+1.76%)
Pre-Market: 06:56AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4777
Bid0.4510 x 900
Ask0.4600 x 1300
Day's Range0.4400 - 0.4695
52 Week Range0.4200 - 2.4500
Avg. Volume4,509,503
Market Cap73.78M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-1.2930
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 18, 2012
1y Target Est5.60
  • American City Business Journals

    The Petri Dish: iSpecimen's founding CEO, longtime COO depart

    Christopher Ianelli, founder and CEO of iSpecimen, is leaving the company following a "mutual agreement" between him and the board of directors.

  • Zacks

    Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

    The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

  • Benzinga

    Despite Regulatory Setback, Spectrum Still "Unique Investment Opportunity," Says Analyst

    Yesterday, the FDA's Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib's (pozi) risk/benefit ratio and concluded that pozi's benefits do not outweigh the risks for the treatment of HER2 exon 20 insertion mutations. Meanwhile, with a newly approved commercial product Rolvedon launching into the $2.3 billion G-CSF space, JMP Securities believes that Spectrum shares still represent a unique investment opportunity with a 34% potent